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Background. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthase
(dhps), in combination with the quintuple mutant involving mutations in both dhps and the gene encoding dihy-
drofolate reductase (dhfr), the so-called sextuple mutant, has been associated with increased placental inflammation
and decreased infant birth weight among women receiving intermittent preventive treatment with sulfadoxine-
pyrimethamine (IPTp-SP) during pregnancy.
Methods. Between 2009 and 2011, delivering women without human immunodeficiency virus infection were
enrolled in an observational study of IPTp-SP effectiveness in Malawi. Parasites were detected by polymerase
chain reaction (PCR); positive samples were sequenced to genotype the dhfr and dhps loci. The presence of
K540E in dhps was used as a marker for the quintuple mutant.
Results. Samples from 1809 women were analyzed by PCR; 220 (12%) were positive for P. falciparum. A total of
202 specimens were genotyped at codon 581 of dhps; 17 (8.4%) harbored the sextuple mutant. The sextuple mutant
was associated with higher risks of patent infection in peripheral blood (adjusted prevalence ratio [aPR], 2.76; 95%
confidence interval [CI], 1.82–4.18) and placental blood (aPR 3.28; 95% CI, 1.88–5.78) and higher parasite densities.
Recent SP use was not associated with increased parasite densities or placental pathology overall and among women
with parasites carrying dhps A581G.
Conclusions. IPTp-SP failed to inhibit parasite growth but did not exacerbate pathology among women infected
with sextuple-mutant parasites. New interventions to prevent malaria during pregnancy are needed urgently.
Keywords. malaria; Plasmodium falciparum; pregnancy; sulfadoxine-pyrimethamine; intermittent preventive
therapy; Malawi; dihydropteroate synthase.
Approximately 32 million women living in malaria-
endemic areas of Africa become pregnant each year
[1]. Malaria during pregnancy is a major, preventable
cause of maternal morbidity, mortality, and poor
birth outcomes in sub-Saharan Africa, particularly in
the first and second pregnancies [2, 3]. Approximately
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20% of deliveries of low-birth-weight infants and up to 200 000
newborn deaths each year occur as a result of malaria during
pregnancy [3].
To prevent malaria during pregnancy in areas with stable
moderate-to-high malaria transmission, the World Health Or-
ganization currently recommends administration of intermit-
tent preventive treatment during pregnancy (IPTp) with
sulfadoxine-pyrimethamine (SP) at each scheduled antenatal
care visit, starting in the second trimester [4, 5]. Increasing par-
asite drug resistance threatens the effectiveness of IPTp-SP. SP
resistance results from the accumulation of mutations in the
Plasmodium falciparum genes encoding dihydrofolate reductase
(dhfr) and dihydropteroate synthase (dhps); resistance increases
with the number of mutant alleles. The K540Emutation in dhps
is a reliable marker for parasites bearing the following 5 mutant
alleles (the so-called dhfr/dhps quintuple mutant): the dhfr sub-
stitutions N51I, C59R, and S108N and the dhps substitutions
A437G and K540E [6]). Although quintuple mutants are rare
in West Africa, they are increasingly found at a high frequency
in eastern and southern Africa [7]. IPTp-SP appears to retain a
level of protective efficacy even in areas with a high frequency of
dhps K540E, despite the fact that SP is no longer effective for
treatment of acute malaria [8–10]. However, quintuple mutants
with an additional dhps mutation, A581G (so-called sextuple
mutants), have been associated with failure of IPTp-SP to im-
prove birth weight [11] and increased placental inflammation
and parasite growth in the presence of SP in an earlier study
from northern Tanzania, which found one of the highest re-
corded prevalence of dhps A581G in Africa to date [12]. This
latter finding, if broadly documented, would suggest that SP po-
tentiates placental pathology in areas of high-grade SP-resistant
parasites, possibly owing to interstrain competition in complex,
polyclonal infections in which highly resistant parasites that
harbor the additional mutation at codon 581 have a survival ad-
vantage under drug pressure over less resistant parasites and
may outcompete them, ultimately leading to better growth of
these parasites than in the absence of SP [12]. This phenome-
non was not confirmed in the second study [11].
Malaria control programs require a better understanding of
whether SP is simply ineffective in the face of the highly resis-
tant sextuple mutant, thereby allowing these parasites to grow
unchecked, or whether under these conditions SP actually pro-
motes the growth of parasites bearing these mutations and
therefore potentially harms pregnant women. Therefore, we
compared parasitologic and morbidity end points at delivery
among parasitemic IPTp-SP recipients in southern Malawi to
investigate whether the sextuple mutant results in a reduced ef-
fectiveness of IPTp-SP to clear or suppress parasite densities or
is potentially fuelling parasite growth and exacerbation of pla-
cental pathology in the presence of SP. In these study sites,
>95% of P. falciparum parasites harbor dhps K540E, but the ad-
ditional mutation at codon 581 has only recently been detected
[13–15]. These sites therefore reflect many other African set-
tings in East and Southern Africa and offer an opportunity to
characterize the parasitologic and clinical consequences of
this emerging drug resistance mutation [16].
METHODS
Study Sites
Women were enrolled from 4 sites in Malawi: Machinga District
Hospital in Liwonde (enrollment period, March through August
2010) and the Blantyre sites, comprising Queen Elizabeth Central
Hospital in Blantyre and facilities in the neighboring villages of
Madziabango and Mpemba (enrollment period, November
2009–January 2011). Transmission of malaria in these areas of
Malawi is stable throughout the year, with a peak between Feb-
ruary and March, shortly after the rainy season. According to the
2010 Demographic and Health Survey, antenatal clinic atten-
dance in Malawi is high: approximately 98% of women reported
at least 1 visit, and 45.5% reported ≥4 visits [17]. The uptake of 2
doses of IPTp-SP, at least one of which had been administered at
the antenatal clinic, was 53.2% in 2012 [18].
Enrollment and Study Procedures
Consenting women with a singleton pregnancy were enrolled at
delivery; women with documented human immunodeficiency
virus infection were excluded. Participant antenatal clinic
cards were examined to obtain the number and timing of
IPTp-SP doses received during pregnancy.
A blood sample was collected prior to delivery for peripheral
smear analysis and measurement of hemoglobin levels, using a
Hemocue Hb 201+ Analyzer (Hemocue, Cypress, California).
Maternal anemia was defined as a hemoglobin level of <11 g/
dL, and severe anemia was defined as a hemoglobin level of
<8 g/dL [19]. At delivery, placental blood, placental tissue,
and cord blood samples were collected and infant birth weight
was measured. Blood smears were stained with Field stains A
and B (azure dye and eosin) (at Machinga District Hospital)
or Giemsa stain (at the Blantyre sites). Parasite densities were
calculated by counting the number of asexual-stage parasites
per 200 white blood cells (at Machinga District Hospital) and
the number per 300 white blood cells (at the Blantyre sites), as-
suming 8000 white blood cells per dL of blood. Blood smears
were considered negative for Plasmodium species if no parasites
were found after counting 1000 (at Machinga District Hospital)
or 500 fields (at the Blantyre sites). All slides were read in du-
plicate, and discordant results resolved by a third reader.
Full-thickness placental biopsy specimens were obtained
from a healthy pericentric area and placed into 10% neutral
buffered formalin at delivery [20]. Biopsy samples were stored
at room temperature until processing and were embedded in
paraffin wax by standard techniques. Paraffin sections were
stained with hematoxylin–eosin and Giemsa stain. Placental
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tissue samples were examined for parasites and pigment, using
the 5-point scale described by Rogerson et al [21]. Active infec-
tion was defined as acute or chronic infections detected by his-
tologic analysis.
Low birth weight was defined as a birth weight of <2500 g. Ges-
tational age was assessed by the Ballard examination within 24
hours of delivery, by trained study nurses. The Ballard score was
used to define both preterm delivery (gestational age, <37 weeks)
and to determine infants who were small for gestational age [22].
Molecular Testing
Parasites were detected by either nested polymerase chain reac-
tion (PCR) [23] or real-time PCR [24]; positive samples were se-
quenced to genotype the dhfr and dhps loci [13, 25]. Not all
specimens could be amplified at all loci; thus, the presence of
dhps K540E was used as a marker for the quintuple mutant.
Statistical Analysis
Statistical analysis was done using SAS, version 9.3 (SAS
Institute, Cary, North Carolina). The analytical population to
determine the associations between parasite genotype and
parasitologic and clinical parameters was restricted to 202
PCR-positive women for whom dhps codon 581 genotyping
data were available. The probability of patent infection (defined
as a PCR-positive and microscopy-positive infection), parasite
densities, and a range of morbidity outcomes were compared
among women infected with sextuple-mutant parasites and
those infected with parasites bearing the wild-type (WT) dhps
codon 581 (99% of which were quintuple mutants). Because a
previous study demonstrated a strong association between parasi-
tologic outcomes and timing of SP dose, irrespective of genotype
[12], a separate comparison was conducted to compare the same
end points among womenwho had received SP in the last 4 weeks
(the maximum anticipated duration of posttreatment prophylaxis
from a single course of SP in this area of highly prevalent SP re-
sistance among parasites) versus those who received SP earlier in
pregnancy or never [26,27]. In addition, we investigated the inter-
action between genotype and the timing of the last SP dose.
Univariable models (unadjusted for potential confounders)
and multivariable models (adjusted for study site and gravidity)
were conducted. In univariable models, groups were compared
using the χ2 test or Fisher exact test, for categorical variables,
and the Student t test, for continuous variables. Poisson regres-
sion models with robust standard errors were used to compare
discrete outcomes and linear regression, using Proc Mixed fit
for continuous outcomes. Results are expressed as crude and
adjusted prevalence ratios (aPRs) or mean differences (or as
the ratio of the mean difference, for log-transformed parasite
counts). A 2-sided P value of <.05 was considered statistically
significant. For PCR-positive, smear-negative samples, we as-
sumed limits of detection of 40 parasites/µL for microscopy
and 5 parasites/µL for PCR. To obtain estimates of the
geometric mean parasite densities (GMPDs), smear-negative
women were treated as interval censored in the analyses, ac-
counting for the limit of detection of microscopy [28].
Ethics
Data from 2 studies that used similar protocols are presented here.
Both studies were approved by the ethical review boards of the
University of Malawi College of Medicine (Blantyre, Malawi).
The study at the Blantyre sites was also approved by the Liverpool
School of Tropical Medicine (Liverpool, United Kingdom); the
study in Machinga District Hospital was approved by the Centers
for Disease Control and Prevention (Atlanta, Georgia). Written
informed consent was obtained from all participating women.
RESULTS
A total of 1851 women were enrolled: 710 from Machinga Dis-
trict Hospital and 1141 from Blantyre. Overall, 117 (6.3%) were
smear positive. Samples from 1809 women (98%) were available
and analyzed by PCR. Of these, 220 (12.1%) had P. falciparum
detected by PCR; 72 of 220 (32.7%) were microscopy positive (in-
dicating patent infection) and 148 of 220 (67.2%) were microsco-
py negative (indicating subpatent infection; Figure 1). Genotypes
at dhps codon 581 were obtained for parasites from 202 women
(91.8%); these constituted the evaluable population for all analy-
ses. A total of 66.3% were primigravidae (G1) or secundigravidae
(G2), and 39.6% reported using an insecticide-treated bed net
(ITN) during the preceding night; these findings were compara-
ble across the 2 groups carrying parasites with each genotype.
Figure 1. Flow of selection of women with infection due to Plasmodium
falciparum with and without the A581G mutation in the gene encoding
dihydropteroate synthase (dhps). Abbreviations: PCR, polymerase chain
reaction; WT, wild type.
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Of the 202 women, 17 harbored parasites bearing the sextu-
ple mutant (8.4%), and 185 (91.6%) were infected with para-
sites bearing the WT allele at codon 581. Overall, 200 samples
(99%) were mutated at dhps codon 540, indicating the pres-
ence of the quintuple mutant, including all 17 samples with
dhps A581G (Table 1). Among the 202 women, 4 (2%) had
not received IPTp-SP, 29 (14%) had received 1 dose, 124
(61%) had received 2 doses, 43 (21%) had received 3 doses,
and 2 (1%) had received 4 doses; 49 women received SP within
4 weeks of delivery.
Associations With dhps A581G
Microscopy-Determined Parasitemia
The presence of dhps A581G was associated with higher risk of
patent infections in both maternal peripheral (aPR, 2.76, 95%
confidence interval [CI], 1.82–4.18) and placental blood (aPR,
3.28; 95% CI, 1.88–5.78; Table 2). After accounting for the limit
of detection of microscopy, the GMPD in samples with dhps
A581G compared, with samples bearing the WT allele at
codon 581, was higher in both maternal peripheral blood (ratio
of GMPD, 9.98; 95% CI, 2.95–33.74) and placental blood (ratio of
Table 1. Baseline Characteristics of 202 Pregnant Women, Overall and by Codon 581 Status of the Gene Encoding Plasmodium
falciparum Dihydropteroate Synthase (dhps)
Characteristic
Overall dhps A581G WT dhps 581
Prevalence Ratio
(95% CI) P Values202 N = 17 N = 185
Blantyre study sitea 121 (59.9) 7 (41.2) 114 (61.6) 0.67 (.37–1.19) .17
Primigravidae or secundigravidae 134 (66.3) 12 (70.6) 122 (65.9) 1.07 (.77–1.48) .68
Used an ITN last night 80 (39.6) 6 (35.3) 74 (40.0) 0.88 (.45–1.72) .71
No. of IPTp-SP doses received
0 4 (2.0) 0 (0.0) 4 (2.2) . . . .25
1 29 (14.4) 1 (5.9) 28 (15.1) . . .
2 124 (61.4) 15 (88.2) 109 (58.9) . . .
3 43 (21.3) 1 (5.9) 42 (22.7) . . .
4 2 (1.0) 0 (0.0) 2 (1.1) . . .
SP receipt within 4 wks of delivery 49 (24.3) 5 (29.4) 44 (23.8) 1.13 (.52–2.46) .75
dhps K540E 200 (99.0) 17 (100.0) 183 (98.9) 1.01 (1.00–1.03) .16
Abbreviations: CI, confidence interval; IPTp-SP, intermittent preventive treatment with sulfadoxine-pyrimethamine; ITN, insecticide-treated bed net; SP, sulfadoxine-
pyrimethamine; WT, wild type.
a All 3 sites in the Blantyre region, described in “Methods“ section, are pooled as theBlantyre study site. All remainingwomenwere recruited atMachingaDistrict Hospital.
Table 2. Effect of the A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthase (dhps), Compared With
Wild-Type dhps Codon 581
Characteristic













Smear positivity, by specimen
Any 14/17 (82.4) 51/185 (27.6) 2.98 (2.17–4.12) <.0001 2.85 (2.02–4.03) <.0001
Maternal 12/17 (70.6) 46/185 (24.9) 2.84 (1.91–4.22) <.0001 2.76 (1.82–4.18) <.0001
Placental 9/17 (52.9) 25/185 (13.5) 3.92 (2.20–6.98) <.0001 3.28 (1.88–5.78) <.0001
Histologic finding of active infection 10/16 (62.5) 121/183 (66.1) 0.95 (.64–1.40) .78 0.99 (.65–1.49) .94
Anemia 6/17 (35.0) 86/185 (46.5) 0.76 (.39–1.47) .41 0.72 (.37–1.40) .33
Hemoglobin level, g/dL 11.2 ± 1.2 11.1 ± 1.6 0.14 (−.67 to .95) .73 0.32 (−.47 to 1.11) .43
Low-birth-weight infant 1/17 (5.9) 20/185 (10.8) 0.54 (.08–3.81) .54 0.68 (.10–4.48) .69
SGA infant 8/16 (50.0) 64/183 (35.0) 1.43 (.84–2.42) .18 1.39 (.78–2.48) .27
Preterm delivery 1/16 (6.3) 21/183 (11.5) 0.54 (.07–3.79) .54 0.78 (.11–5.45) .80
Infant birth weight, g 3019 ± 595 2922 ± 424 96.5 (−123.5 to 316.5) .39 51 (−154 to 256) .63
Infant gestational age, wksc 40.1 ± 2.1 39.5 ± 2.1 0.6 (−1.7 to .5) .28 −0.04 (−.85 to .77) .93
Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; PR, prevalence ratio; SGA, small for gestational age; WT, wild type.
a Data are no. of women with the characteristic/no. evaluated (%) or mean value ± range.
b Analysis adjusted for site, gravidity, and sulfadoxine-pyrimethamine use within 4 weeks of delivery.
c Data are for infants delivered by 16 women with mutant infection and by 183 women with WT infection.
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GMPD, 4.63; 95% CI, 1.75–12.26). When restricted only to those
women who had received 2 antenatal doses of SP, the higher risk
of patent infections persisted in both maternal peripheral blood
(aPR, 2.48; 95% CI, 1.52–4.05) and placental blood (aPR, 2.28;
95% CI, 1.28–4.05). When restricted only to women with patent
infections, dhps A581G was not associated with an increased
GMPD, compared with those with WT dhps 581 (Table 3). No
dose-response effect of SP on parasite densities was observed
among the group as a whole or among women infected with par-
asites with the WT allele at codon 581 (Table 4). We could not
Table 3. Geometric Mean Parasite Densities (GMPDs) Overall and Among Smear-Positive Women, Stratified by Plasmodium falciparum
Dihydropteroate Synthase Gene (dhps) Codon 581 Status and Receipt of Intermittent Preventive Treatment With Sulfadoxine-
Pyrimethamine Within 4 Weeks Before Delivery
Variable
All Women Nonrecipients of SP Recipients of SP
P, Nonrecipients
vs RecipientsNo. GMPD (95% CI) No. GMPD (95% CI) No. GMPD (95% CI)
Overall
Maternal peripheral parasitemia
Overall 202 33 (23–48) 153 34 (22–51) 49 31 (15–65) .84
WT dhps 581 185 27 (19–39) 141 28 (18–43) 44 24 (12–51) .69
dhps A581G 17 266 (77–920) 12 268 (74–966) 5 263 (15–4691) .94
P, mutant vs WT .0002 .003 .03
Placental parasitemia
Overall 202 17 (12–23) 153 18 (12–25) 49 14 (8–25) .36
WT dhps 581 185 15 (11–20) 141 16 (11–23) 44 12 (7–20) .25
dhps A581G 17 67 (26–174) 12 66 (20–220) 5 73 (18–295) .97
P, mutant vs WT .002 .02 .01
Smear positive
Maternal peripheral parasitemia
Overall 61 824 (530–1283) 47 808 (490–1334) 14 882 (344–2260) .87
WT dhps 581 49 787 (479–1293) 38 824 (463–1469) 11 672 (261–1731) .72
dhps A581G 12 995 (378–2619) 9 737 (281–1930) 3 2454 (248–24 244) .27
P, mutant vs WT .68 .86 .24
Placental parasitemia
Overall 42 274 (153–491) 33 319 (162–627) 9 162 (59–440) .30
WT dhps 581 33 255 (120–539) 27 297 (129–683) 6 130 (27–631) .37
dhps A581G 9 314 (182–542) 6 387 (200–748) 3 206 (94–449) .25
P, mutant vs WT .81 .79 .73
All models controlled for study site and gravidity.
Abbreviations: CI, confidence interval; SP, sulfadoxine-pyrimethamine; WT, wild type.
Table 4. Geometric Mean Parasite Densities (GMPDs) Overall and Among Women Infected With Plasmodium falciparum Bearing Wild-




P Values0 1 2 ≥3
Overall
Women, no. 4 29 124 45
Maternal GMPD (95% CI) 29 (2–344) 27 (11–69) 33 (21–51) 40 (17–94) .47
Placental GMPD (95% CI) 36 (2–620) 19 (8–46) 18 (12–26) 12 (7–21) .12
Infected with wild-type dhps 581
Women, no. 4 28 109 44
Maternal GMPD (95% CI) 29 (2–344) 24 (9–61) 26 (16–41) 34 (15–78) .52
Placental GMPD (95% CI) 36 (2–620) 16 (7–38) 16 (11–23) 11 (6–19) .13
Abbreviation: CI, confidence interval.
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explore a dose-response effect among the women with dhps
A581G because only 1 of 17 women had not received SP, and
only 1 had received >2 doses.
Histopathologic Findings
dhps A581G was not associated with an increased risk of active
infection diagnosed on the basis of histologic analysis, both
among all women (aPR, 0.99; 95% CI, .65–1.49) and among
those who had received 2 doses of IPTp-SP (aPR, 0.93; 95% CI,
.56–1.54). Compared with women who received none or only 1
dose of SP, receipt of at least 2 doses of IPTp-SP was associated
with a decreased risk of having active infection diagnosed on
the basis of histologic analysis (aPR, 0.76; 95% CI, .62–.92).
Maternal Anemia and Birth Outcomes
There was no difference inmean hemoglobin level (±SD) between
women harboring parasites with and those harboring parasites
without the dhps 581G allele (11.22 ± 1.2 g/dL and 11.08 ± 1.6
g/dL, respectively; adjusted mean difference, 0.32 g/dL [95%
CI], −.47 to 1.11 g/dL). There were no differences in the frequen-
cies of women who had preterm delivery and those who had
small-for-gestational-age infants (Table 2). Similarly, there was
no difference in the prevalence of anemia (Table 2) or severe ane-
mia (mutant vs WT, 0% vs 2.5%; P = 1.00). Among infants deliv-
ered by the 17 women with mutant infections, adjusted mean
birth weights were 51 g higher (P = .63), and the prevalence of
low birth weight was lower (5.9% vs 10.8%; P = .54).
Influence of Timing of IPTp-SP, Overall and by Genotype
Recent receipt of SP prior to delivery has been hypothesized to
exacerbate placental pathology in resistant, multiclonal malaria
infections. Therefore, we explored the impact of recent SP use
(within 4 weeks of delivery) on outcomes. There was no signifi-
cant difference in GMPD between women who received SP
Figure 2. Associations between binomial variables (A) and continuous variables (B) and parasitologic and morbidity end points, by time since last dose of
sulfadoxine-pyrimethamine (SP), among 202 women who tested positive for Plasmodium falciparum by polymerase chain reaction. Abbreviations: CI,
confidence interval; dhps, dihydropteroate synthase; Hb, hemoglobin; SD, standard deviation; SGA, small for gestational age; WT, wild type.
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recently and those who had not (Figure 2A). There was no dif-
ference in the risk of patent maternal peripheral or placental in-
fection when comparing women with and without recent SP use
overall (aPR, 0.94; 95% CI, .57–1.55), among women with WT
infections (aPR, 0.84; 95% CI, .68–1.73), or among the 17
women infected with parasites bearing dhps 581G (aPR, 1.08;
95% CI, .68–1.73).
Among women who received IPTp-SP and had results of his-
tologic analyses (n = 199), receipt of recent SP (n = 47) was as-
sociated with a nonsignificantly lower prevalence of active
infection, based histopathologic findings (aPR, 0.77; 95% CI,
.58–1.01; P = .06), when controlling for site, gravidity, and pres-
ence of the dhps A581G mutation.
Recent receipt of SP was not associated with an increased or
decreased risk of anemia or with a significant difference in ma-
ternal hemoglobin level, although hemoglobin levels tended to
be highest in recent recipients of SP (Figure 2B).
DISCUSSION
In our sites, 8.4% of delivering women with P. falciparum infec-
tion harbored sextuple-mutant parasites. The sextuple mutant
was associated with a decreased effectiveness of IPTp-SP, but
in contrast to a previous observational study from Tanzania
[12], there was no indication that use of SP in the last month
was associated with higher prevalence or parasite densities, sug-
gesting that, although SP use is of decreased benefit in the
presence of the sextuple mutant, there was no evidence that
its use was harmful per se.
Compared with women infected with parasites with the wild
type allele at dhps codon 581, women infected with P. falcipa-
rum bearing dhps A581G had higher parasite densities and thus
were more likely to have patent parasitemia. This finding, which
has been reported previously, suggests that this additional mu-
tation confers a greater level of resistance than the quintuple
mutant alone, resulting in a failure of SP to successfully sup-
press parasite densities to below the levels of microscopic
detection. Despite this, in our study, the presence of this mutant
allele was not associated with worsened clinical morbidity, as
manifested by lower maternal hemoglobin concentrations at
birth, birth weight, or birth size, or with worsened histologic
features, in contrast to what has been reported from Tanzania
[11, 12], although this may be a result of insufficient power in
our study.
One of the studies from Tanzania suggested that giving SP
was potentially harmful in areas with very high levels of SP re-
sistance [12]. In that study, the receipt of IPTp-SP was associ-
ated with a higher mean parasite density, a more-intense
placental inflammation, and a greater density of parasites bear-
ing dhps A581G; additionally, a dose-response relationship was
evident, in which the highest densities were reported among
women who had received SP in the last few weeks before preg-
nancy or who had received multiple doses of SP. This finding
was reported for the overall sample (including infections with
Figure 2 continued.
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WT parasites). It was hypothesized that this resulted from a
phenomenon of competitive facilitation. If these findings were
confirmed, they would have major implications for malaria con-
trol programs during pregnancy, as they would suggest that, in
areas where highly resistant sextuple mutants circulate, IPTp-SP
may not simply lack efficacy, but rather may exacerbate placen-
tal malaria and harm women and their newborns. Neither our
study nor the second study in Tanzania, conducted in an area
where the prevalence of sextuple-mutant parasites was 43%
among infected women with no SP exposure, have confirmed
this finding [11]. In our study, recent SP use was not associated
with the prevalence or density of parasites. The prevalence of
patent peripheral malaria at delivery overall was similar
among recent recipients of SP (28.6%), compared with
women who had not received SP recently (33.3%), irrespective
of parasite genotype. The risk of acute or chronic infections (ie,
active infections), as assessed by histologic analysis, was lower in
recent recipients of SP, compared with those who received SP >4
weeks prior to delivery (53% vs 70%; aPR, 0.77 [95% CI, .58–
1.01]; P = .06). We were not able to explore a dose-response
in women bearing parasites carrying dhps A581G because 15
of the 17 women had received 2 doses of SP. Among the 185
women with the WT dhps codon 581 infection, there was no
trend toward higher parasite densities with increasing doses
of SP, but the number of women receiving no SP (n = 4) was
too small to allow for a meaningful analysis of the dose-
response relationship. Furthermore, in the overall sample of
1852 women (including the women for whom PCR did not de-
tect parasites at delivery), recent SP use was associated with a
lower risk of infection detected by histologic analysis, compared
with women who received their last dose of SP earlier in preg-
nancy (aPR, 0.63; 95% CI, .49–.81; P = .0003; data not shown).
Taken together, our findings indicate that, in southern Malawi,
SP delivered as IPTp reduces the risk of infection among the
majority of women but that this beneficial effect is significantly
reduced or absent among women bearing parasites carrying
dhps A581G.
It is possible that these differences from the first Tanzanian
study [12] regarding recent use of SP prior to delivery are
explained by a difference in the level of resistance or other dif-
ferences in the parasite population. dhps A581G was still rare in
southern Malawi (prevalence, 1.46% [95% CI, 1.3%–1.62%] at
the first antenatal clinic visit [data not shown] and 8.4% at de-
livery), compared with northern Tanzania. The very small size
of the SP-naive group in our cohort (n = 4 overall) reduced our
ability to look at a dose-response relationship and may have
hampered our ability to detect any potential harm mediated
by SP. An additional possibility is that unidentified mutations
in addition to dhps A581G are involved that serve to mediate
parasite fitness when exposed to SP, either within the enzymes
targeted by the drugs or in other targets; it has recently been
shown that these mutant lineages have emerged independently,
supporting the premise that other mutations may be present in
the Tanzanian parasites [29].
Although the overall sample size is reasonable, the small num-
ber of women with mutant infections (n = 17) precluded more-
comprehensive analysis of morbidity outcomes. As mentioned
above, the vast majority of women with mutations received 2
doses of IPTp-SP; thus, it was not possible to examine the effect
of the dose-response relationship for IPTp-SP doses on parasito-
logic outcomes or to further explore the phenomenon of com-
petitive facilitation. Thus, although no significant association
between the presence of dhps A581G and low birth weight or
anemia was noted, this may simply reflect a lack of power in this
observational study, rather than a true lack of association. Fur-
thermore, only 12 of 17 women with dhps A581G had parasites
detectable by microscopy, and this may have further limited our
ability to detect changes in birth weight.
This is the third study implicating the sextuple mutant in the
failure to prevent the consequences of antenatal malaria, either
by increased parasite densities (as in this study and the study by
Harrington et al [12]), increased placental inflammation [12], or
decreased birth weight [11]. Our data suggest that, while the
presence of the sextuple mutant is associated with a higher like-
lihood of patent parasitemia, this effect seems to be indepen-
dent of the timing of IPTp-SP use, and there was no evidence
that parasite growth was fuelled by the presence of SP. Thus, al-
though the sextuple-mutant haplotype potentiates clinical resis-
tance to SP and attenuates the beneficial impacts of IPTp-SP,
antenatal receipt of IPTp-SP among women harboring these
highly resistant parasites was not associated with harm to the
pregnant women or their offspring in Malawi. Fortunately, at
present, these highly resistant sextuple mutants are found in a
limited number of places in sub-Saharan Africa [16], although
as these mutants spread, the impact of IPTp-SP will diminish. It
is critical to continue monitoring for the emergence of sextuple-
mutant P. falciparum and to improve our understanding of the
influence of this mutation on IPTp-SP effectiveness. Future bio-
chemical or molecular genetic analyses will be useful adjuncts to
understanding these geographical and parasitologic differences
in the impacts of IPTp-SP reported to date. Finally, our results
stress the urgent need for therapeutic alternatives to IPTp-SP,
including new drugs or strategies, such as intermittent screen-
ing and treatment.
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